Maseeh uz Zaman, Nosheen Fatima, Unaiza Zaman, Areeba Zaman, Sidra Zaman


PET/MRI being an FDA approved hybrid imaging modality has significantly higher soft tissue characterization and simultaneous image acquisition gives near-perfect image coregistration as well. Since MRI is considered as standard of care in workup of abdominopelvic oncologic malignancies, addition of PET based metabolic information will definitely enhance the accuracy in staging, restaging and response assessment. Since PET/MRI enables more appropriate management than PET/CT in abdominopelvic malignancies, a histology-based triage of patients to either PET/MRI or PET/CT may be meaningful.

Full Text:




. Cabello J, Ziegler SI. Advances in PET/MR instrumentation and image reconstruction. Br J Radiol 2018;91(1081):20160363.

. Schaarschmidt BM, Grueneisen J, Heusch P, Gomez B, Umutlu L, Ruhlmann V, Krumme S, et al. Does 18F-FDG PET/MRI reduce the number of indeterminate abdominal incidentalomas compared with 18F-FDG PET/ CT? Nucl Med Commun 2015;36(6):588–95

. Turkbey B, Mena E, Shih J, Pinto P, Merino M, Lindenberg M, et al. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. Radiology 2014;270(3):849–56.

. Liu Y, Wen Z, Yang X, Lu B, Xiao X, Chene Y, et al. Lymph node metastasis in rectal cancer: comparison of MDCT and MR imaging for diagnostic accuracy. Abdom Radiol (NY) 2019;44(11):3625–631.

. Pangarkar S, Mistry K, Choudhari A, Smriti V, Ahuja A, Katdare A, et al. Accuracy of MRI for nodal restaging in rectal cancer: a retrospective study of 166 cases. Abdom Radiol (NY) 2021;46(2):498– 505.

. Furtado FS, Ferrone CR, Lee SI, Vangel M, Rosman A, Weekes C, et al. Impact of PET/MRI in the treatment of pancreatic adenocarcinoma: a retrospective cohort study. Mol Imaging Biol 2021;23(3):456–66.

. Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, et al. Early response assessment in pancreatic ductal adenocarcinoma through integrated PET/MRI. AJR Am J Roentgenol 2018;211(5):1010–19

. Ferrone C, Goyal L, Qadan M, Gervais D, Sahani DV, Zhu AX, et al. Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2020;47(8):1871–84.

. Ponisio MR, Fowler KJ, Dehdashti F. The emerging role of PET/MR imaging in gynecologic cancers. PET Clin 2016;11(4):425–40.

. Jónsdóttir B, Ripoll MA, Bergman A, Silins I, Poromaa IS, Ahlström H, et al. Validation of 18F-FDG PET/MRI and diffusion-weighted MRI for estimating the extent of peritoneal carcinomatosis in ovarian and endometrial cancer: a pilot study. Cancer Imaging 2021;21(1):34

. Wright JD, Matsuo K, Huang Y, Tergas AI, Hou JY, Colladoet FK, al. Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics cervical cancer staging guidelines. Obstet Gynecol 2019;134(1):49–57

. Matsuo K, Machida H, Mandelbaum RS, Konishi I, Mikami M. Validation of the 2018 FIGO cervical cancer staging system. Gynecol Oncol 2019;152(1):87–93.

. Schwartz M, Gavane SC, Bou-Ayache J, Kolev V, Zakashansky K, Hayes MP, et al. Feasibility and diagnostic performance of hybrid PET/MRI compared with PET/CT for gynecological malignancies: a prospective pilot study. Abdom Radiol (NY) 2018;43(12):3462–67.

. Samarin A, Burger C, Wollenweber SD, Crook DW, Burger IA, Schmid DT, et al. PET/MR imaging of bone lesions: implications for PET quantification from imperfect attenuation correction. Eur J Nucl Med Mol Imaging 2012;39(7):1154–60.

. Sawicki LM, Grueneisen J, Buchbender C, Schaarschmidt BM, Gomez B, Ruhlmann V, et al. Evaluation of the outcome of lung nodules missed on 18F-FDG PET/MRI compared with 18F-FDG PET/CT in patients with known malignancies. J Nucl Med 2016;57(1):15–20.


  • There are currently no refbacks.

© Copyright PJR 2008-